{"id":67299,"date":"2026-06-04T14:40:57","date_gmt":"2026-06-04T06:40:57","guid":{"rendered":"https:\/\/flcube.com\/?p=67299"},"modified":"2026-06-04T14:44:52","modified_gmt":"2026-06-04T06:44:52","slug":"medtronic-reports-strong-q4-and-fy26-results-with-6-6-organic-growth-cardiac-ablation-solutions-surge-78","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67299","title":{"rendered":"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Medtronic plc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/MDT:NYSE\">NYSE: MDT<\/a>) announced financial results for its <strong>fourth quarter (Q4)<\/strong> and <strong>fiscal year 2026 (FY26)<\/strong>, which concluded on <strong>April 24, 2026<\/strong>. The global medical technology leader delivered <strong>Q4 revenue of $9.8 billion<\/strong>, representing <strong>6.6% organic growth<\/strong>, while achieving <strong>full-year FY26 revenue of $36.4 billion<\/strong> with <strong>5.8% organic growth<\/strong>. <\/p>\n\n\n\n<h2 id=\"h-quarterly-financial-performance-summary\" class=\"wp-block-heading\">Quarterly Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q4 FY26<\/th><th>Year-over-Year Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>$9.8 billion<\/td><td>+6.6% organic<\/td><\/tr><tr><td><strong>Cardiac Ablation Solutions<\/strong><\/td><td>Not disclosed<\/td><td>+78% global (+124% US)<\/td><\/tr><tr><td><strong>Cardiovascular<\/strong><\/td><td>$3.8 billion<\/td><td>+10.1%<\/td><\/tr><tr><td><strong>Medical Surgical<\/strong><\/td><td>$2.4 billion<\/td><td>+5.1%<\/td><\/tr><tr><td><strong>Neuroscience<\/strong><\/td><td>$2.8 billion<\/td><td>+3.0%<\/td><\/tr><tr><td><strong>Diabetes<\/strong><\/td><td>$837 million<\/td><td>+8.1%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">All growth figures represent organic performance, excluding the impact of foreign currency fluctuations and acquisitions.<\/p>\n\n\n\n<h2 id=\"h-business-group-performance-highlights\" class=\"wp-block-heading\">Business Group Performance Highlights<\/h2>\n\n\n\n<h3 id=\"h-cardiovascular-10-1-to-3-8-billion\" class=\"wp-block-heading\">Cardiovascular (+10.1% to $3.8 billion)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cardiac Rhythm Management<\/strong> delivered mid-single-digit growth<\/li>\n\n\n\n<li><strong>Cardiac Pacing Therapies<\/strong> and <strong>Defibrillation Solutions<\/strong> showed continued strength<\/li>\n\n\n\n<li><strong>Micra<\/strong> platform achieved mid-teens growth<\/li>\n\n\n\n<li><strong>OmniaSecure<\/strong> launched successfully in the US market with strong initial adoption<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-medical-surgical-5-1-to-2-4-billion\" class=\"wp-block-heading\">Medical Surgical (+5.1% to $2.4 billion)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Acute Care &amp; Monitoring<\/strong> led segment performance<\/li>\n\n\n\n<li><strong>Endoscopy<\/strong> contributed significantly to growth<\/li>\n\n\n\n<li>Broad-based recovery across procedural volumes<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-neuroscience-3-0-to-2-8-billion\" class=\"wp-block-heading\">Neuroscience (+3.0% to $2.8 billion)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Steady performance across neurovascular and neuromodulation portfolios<\/li>\n\n\n\n<li>Consistent demand for chronic pain and movement disorder therapies<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-diabetes-8-1-to-837-million\" class=\"wp-block-heading\">Diabetes (+8.1% to $837 million)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Continued momentum in insulin delivery systems<\/li>\n\n\n\n<li>Strong international performance complementing US market share gains<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-growth-drivers\" class=\"wp-block-heading\">Strategic Growth Drivers<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cardiac Ablation Solutions<\/strong> emerged as the standout performer with <strong>78% global growth<\/strong>, including an exceptional <strong>124% increase in US revenue<\/strong>, reflecting strong adoption of next-generation ablation technologies for atrial fibrillation treatment<\/li>\n\n\n\n<li><strong>Innovation Pipeline:<\/strong> Recent product launches, including OmniaSecure, demonstrate successful commercialization of R&amp;D investments<\/li>\n\n\n\n<li><strong>Procedural Recovery:<\/strong> Full normalization of elective and semi-elective procedures post-pandemic continues to benefit all business segments<\/li>\n\n\n\n<li><strong>Geographic Diversification:<\/strong> Balanced performance across developed and emerging markets provides revenue stability<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-full-year-fy26-achievement\" class=\"wp-block-heading\">Full-Year FY26 Achievement<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Revenue:<\/strong> $36.4 billion<\/li>\n\n\n\n<li><strong>Organic Growth:<\/strong> 5.8%<\/li>\n\n\n\n<li><strong>Consistent Execution:<\/strong> Delivered steady quarterly performance throughout the fiscal year<\/li>\n\n\n\n<li><strong>Market Leadership:<\/strong> Maintained #1 or #2 position in 25 of 27 product categories<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The results reflect Medtronic&#8217;s successful execution of its strategic priorities, including innovation acceleration, operational excellence, and market expansion initiatives.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Medtronic&#8217;s financial performance and market position. Actual results may differ materially due to risks including regulatory approvals, competitive dynamics, supply chain constraints, and macroeconomic conditions affecting healthcare spending.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/Press-Release-FY26Q4-vfinal1-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Press-Release-FY26Q4-vfinal1-1.\"><\/object><a id=\"wp-block-file--media-47e18ea0-8c6d-49cf-958e-f0143f8f6d38\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/Press-Release-FY26Q4-vfinal1-1.pdf\">Press-Release-FY26Q4-vfinal1-1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/Press-Release-FY26Q4-vfinal1-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-47e18ea0-8c6d-49cf-958e-f0143f8f6d38\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/Q4_FY26_Financial_Schedules.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Q4_FY26_Financial_Schedules.\"><\/object><a id=\"wp-block-file--media-2a76d126-8b66-4bca-ae46-2ee8e5cbc310\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/Q4_FY26_Financial_Schedules.pdf\">Q4_FY26_Financial_Schedules<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/Q4_FY26_Financial_Schedules.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2a76d126-8b66-4bca-ae46-2ee8e5cbc310\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year&#8230;<\/p>\n","protected":false},"author":1,"featured_media":67304,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,233,1031],"class_list":["post-67299","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-medtronic","tag-nyse-mdt"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which concluded on April 24, 2026. The global medical technology leader delivered Q4 revenue of $9.8 billion, representing 6.6% organic growth, while achieving full-year FY26 revenue of $36.4 billion with 5.8% organic growth.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67299\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%\" \/>\n<meta property=\"og:description\" content=\"Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which concluded on April 24, 2026. The global medical technology leader delivered Q4 revenue of $9.8 billion, representing 6.6% organic growth, while achieving full-year FY26 revenue of $36.4 billion with 5.8% organic growth.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67299\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T06:40:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-04T06:44:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67299#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67299\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%\",\"datePublished\":\"2026-06-04T06:40:57+00:00\",\"dateModified\":\"2026-06-04T06:44:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67299\"},\"wordCount\":370,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67299#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0401.webp\",\"keywords\":[\"Finanical Reports\",\"Medtronic\",\"NYSE: MDT\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67299#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67299\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67299\",\"name\":\"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67299#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67299#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0401.webp\",\"datePublished\":\"2026-06-04T06:40:57+00:00\",\"dateModified\":\"2026-06-04T06:44:52+00:00\",\"description\":\"Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which concluded on April 24, 2026. The global medical technology leader delivered Q4 revenue of $9.8 billion, representing 6.6% organic growth, while achieving full-year FY26 revenue of $36.4 billion with 5.8% organic growth.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67299#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67299\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67299#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0401.webp\",\"width\":1080,\"height\":608,\"caption\":\"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67299#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78% - Insight, China&#039;s Pharmaceutical Industry","description":"Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which concluded on April 24, 2026. The global medical technology leader delivered Q4 revenue of $9.8 billion, representing 6.6% organic growth, while achieving full-year FY26 revenue of $36.4 billion with 5.8% organic growth.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67299","og_locale":"en_US","og_type":"article","og_title":"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%","og_description":"Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which concluded on April 24, 2026. The global medical technology leader delivered Q4 revenue of $9.8 billion, representing 6.6% organic growth, while achieving full-year FY26 revenue of $36.4 billion with 5.8% organic growth.","og_url":"https:\/\/flcube.com\/?p=67299","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-04T06:40:57+00:00","article_modified_time":"2026-06-04T06:44:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67299#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67299"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%","datePublished":"2026-06-04T06:40:57+00:00","dateModified":"2026-06-04T06:44:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67299"},"wordCount":370,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=67299#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0401.webp","keywords":["Finanical Reports","Medtronic","NYSE: MDT"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67299#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67299","url":"https:\/\/flcube.com\/?p=67299","name":"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=67299#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=67299#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0401.webp","datePublished":"2026-06-04T06:40:57+00:00","dateModified":"2026-06-04T06:44:52+00:00","description":"Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which concluded on April 24, 2026. The global medical technology leader delivered Q4 revenue of $9.8 billion, representing 6.6% organic growth, while achieving full-year FY26 revenue of $36.4 billion with 5.8% organic growth.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67299#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67299"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=67299#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0401.webp","width":1080,"height":608,"caption":"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67299#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0401.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67299"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67299\/revisions"}],"predecessor-version":[{"id":67305,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67299\/revisions\/67305"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/67304"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}